drugset / Trial / NCT03106623

Study of ONO-8577 in Patients With Overactive Bladder

NCT03106623

Phase 2 Completed 207 enrolled Ono Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study is to evaluate the efficacy and safety of ONO-8577 compared to combination of solifenacin succinate and mirabegron or placebo for overactive bladder

Timeline

Start
2017-04-07
Primary completion
2017-08-29
Completion
2017-09-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirabegron Other / unclassified Oral
Subject ONO-8577 Unknown Oral
Comparator Solifenacin Small molecule Oral

Indications